RecruitingPhase 3NCT04284839

The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial


Sponsor

Population Health Research Institute

Enrollment

3,500 participants

Start Date

Jul 18, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18 years at the time of enrolment,
  • Open heart surgery in the last 10 days,
  • Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
  • Informed consent from either the patient or a substitute decision-maker.

Exclusion Criteria12

  • Mechanical valve replacement,
  • Antiphospholipid syndrome (triple positive),
  • Severe renal failure (Cockcroft-Gault equation; creatinine clearance \<15 ml/min),
  • Known significant liver disease (Child-Pugh classification B and C),
  • Left ventricular thrombus,
  • Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
  • Known contraindication for any DOAC or VKA,
  • Women who are pregnant, breastfeeding, or of childbearing potential,
  • Surgery including left ventricular assist device implantation or cardiac transplantation,
  • Previously enrolled in this trial,
  • Follow-up not possible,
  • History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDOAC

Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

DRUGVKA

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.


Locations(19)

St Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Royal Melbourne Hospital, University of Melbourne

Parkville, Victoria, Australia

University of Alberta Hospital

Edmonton, Alberta, Canada

University of British Columbia

Vancouver, British Columbia, Canada

St. Boniface Hospital

Winnipeg, Manitoba, Canada

Saint John Regional Hospital

Saint John, New Brunswick, Canada

Health Science Centre

St. John's, Newfoundland and Labrador, Canada

Health Sciences North Research Institute

Greater Sudbury, Ontario, Canada

Hamilton General Hospital

Hamilton, Ontario, Canada

Sunnybrook Hospital

Toronto, Ontario, Canada

Toronto General Hospital

Toronto, Ontario, Canada

Montreal Heart Institute

Montreal, Quebec, Canada

Hôpital Sacré-Coeur de Montréal

Montreal, Quebec, Canada

IUCPQ-ULaval

Québec, Quebec, Canada

Heart Center Leipzig

Leipzig, Saxony, Germany

University Hospital Jena

Jena, Thuringia, Germany

University Hospital Bonn Heart Center

Bonn, Germany

West-German Heart and Vascular Center, University of Duisburg-Essen

Essen, Germany

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04284839